These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38183861)

  • 1. Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19.
    Roy V; Buonora M; Simon C; Dooling B; Joudrey P
    Int J Drug Policy; 2024 Feb; 124():104302. PubMed ID: 38183861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
    Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
    Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
    Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
    Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State guidance and system changes related to COVID-19: Impact on opioid treatment programs.
    Fuller DB; Gryczynski J; Schwartz RP; Halsted C; Mitchell SG; Whitter M
    J Subst Use Addict Treat; 2024 Mar; 158():209214. PubMed ID: 38042301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
    Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
    Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
    [No Abstract]   [Full Text] [Related]  

  • 6. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
    Brothers S; Viera A; Heimer R
    J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial of implementation facilitation to increase timely admission to methadone treatment.
    Gryczynski J; Mitchell SG; Whitter M; Fuller D; Mitchell MM; Edelman EJ; Schwartz RP
    J Subst Use Addict Treat; 2024 Jul; 162():209375. PubMed ID: 38642889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
    López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
    J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methadone dosing at New York State opioid treatment programs following initial revisions to federal regulations.
    Jordan AE; Bachhuber MA; Tuazon E; Jimenez C; Lincourt P; Hussain S; Rubinfeld J; Cunningham CO
    Drug Alcohol Depend; 2024 May; 258():111283. PubMed ID: 38581920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.
    Levander XA; Hoffman KA; McIlveen JW; McCarty D; Terashima JP; Korthuis PT
    Addict Sci Clin Pract; 2021 Dec; 16(1):72. PubMed ID: 34895346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs.
    Krawczyk N; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Bandara S
    J Addict Med; 2022 Nov-Dec 01; 16(6):645-652. PubMed ID: 35165225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
    Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
    J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids.
    Panwala V; Thorn E; Amiri S; Socias ME; Lutz R; Amram O
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):597-605. PubMed ID: 37433122
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
    Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
    J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives.
    Hatch-Maillette MA; Peavy KM; Tsui JI; Banta-Green CJ; Woolworth S; Grekin P
    J Subst Abuse Treat; 2021 May; 124():108223. PubMed ID: 33342667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in methadone take-home dosing before and after COVID-19.
    Amram O; Amiri S; Thorn EL; Lutz R; Joudrey PJ
    J Subst Abuse Treat; 2022 Feb; 133():108552. PubMed ID: 34304950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment provider perceptions of take-home methadone regulation before and during COVID-19.
    Madden EF; Christian BT; Lagisetty PA; Ray BR; Sulzer SH
    Drug Alcohol Depend; 2021 Nov; 228():109100. PubMed ID: 34600251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid treatment program culture and philosophy: Views of OTP staff and state officials on implementing interim methadone treatment.
    Burruss-Cousins K; Mitchell SG; Gryczynski J; Whitter M; Fuller D; Ibrahim A; Schwartz RP
    J Subst Use Addict Treat; 2024 Feb; 157():209265. PubMed ID: 38103832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy.
    Krawczyk N; Rivera BD; Levin E; Dooling BCE
    Lancet Public Health; 2023 Mar; 8(3):e238-e246. PubMed ID: 36841564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years.
    Bortz C; Armistead I; Bonaguidi A; Coyle DT
    J Subst Use Addict Treat; 2024 Jun; 161():209342. PubMed ID: 38513975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.